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Abstract
Bluetongue virus (BTV) can infect most species of domestic and wild ruminants causing substantial morbidity and mortality
and, consequently, high economic losses. In 2006, an epizootic of BTV serotype 8 (BTV-8) started in northern Europe that
caused significant disease in cattle and sheep before comprehensive vaccination was introduced two years later. Here, we
evaluate the potential of equine herpesvirus type 1 (EHV-1), an alphaherpesvirus, as a novel vectored DIVA (differentiating
infected from vaccinated animals) vaccine expressing VP2 of BTV-8 alone or in combination with VP5. The EHV-1
recombinant viruses stably expressed the transgenes and grew with kinetics that were identical to those of parental virus in
vitro. After immunization of mice, a BTV-8-specific neutralizing antibody response was elicited. In a challenge experiment
using a lethal dose of BTV-8, 100% of interferon-receptor-deficient (IFNAR
2/2) mice vaccinated with the recombinant EHV-1
carrying both VP2 and VP5, but not VP2 alone, survived. VP7 was not included in the vectored vaccines and was successfully
used as a DIVA marker. In summary, we show that EHV-1 expressing BTV-8 VP2 and VP5 is capable of eliciting a protective
immune response that is distinguishable from that after infection and as such may be an alternative for BTV vaccination
strategies in which DIVA compatibility is of importance.
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Introduction
Bluetongue virus (BTV), the prototype of the genus Orbivirus
within the family Reoviridae, is the causative agent of bluetongue
disease in many species of domestic ruminants, especially sheep.
The virus is highly infectious but not contagious; it is transmitted to
ruminants by biting midges belonging to the genus Culicoides [1].
BTV has a genome composed of 10 segments of double-stranded
RNA that encode for 7 structural proteins (VP1-VP7) and 5 non-
structural proteins (NS1, NS2, NS3/3a, NS4) [2]. Of these, VP2
and VP5 are the major structural proteins forming the outer capsid
of the virus particle. VP2 is the main determinant of BTV serotype
and is responsible for receptor binding, hemagglutination, and
induction of serotype-specific neutralizing antibodies, while VP5
influences virus neutralization through its conformational interac-
tion with VP2 [3,4]. VP7 and VP3 are the major core proteins and
play important roles withrespect to the structural integrity of virions
[3]. At present, 26 distinct serotypes of BTV (BTV-1 to -26) are
recognized, between which there is only little cross-protection, a fact
that complicates vaccination strategies [3,5,6].
BTV was thought to circulate only in tropical and sub-tropical
regions; however, an unusual epizootic of BTV serotype 8 (BTV-8)
started in central and northern Europe in 2006, affecting both
sheep and cattle. During the following years, BTV-8 has spread
rapidly throughout Central Europe and caused massive economic
losses [7,8]. For safety reasons, only inactivated whole virus
vaccines against several serotypes of BTV, including serotype 8,
are now commercially available in Europe. The vaccines are
highly efficacious in reducing clinical disease and BTV circulation
[7]. Preparations of structurally intact BTV virions induce a broad
immune response to virtually all BTV structural proteins and, in
some cases, even non-structural proteins dependent on the
production system [9]. Widespread use of such vaccines, therefore,
confounds serological diagnosis and surveillance. The inability to
differentiate between infected and vaccinated animals is of concern
particularly in cattle, which are usually asymptomatic after BTV
infection but can still spread the virus [10]. One possible approach
to a vaccination strategy that allows the differentiation of infected
from vaccinated animals (DIVA) is the use of recombinant
vaccines expressing only a subset of BTV proteins. Proteins not
included in the vaccine can then be used as negative markers.
Promising results were reported using diverse poxviruses as live
vectors for delivery of BTV antigens, mainly VP2, VP5 and VP7
[11,12,13,14].
This study presents a different approach, using equine
herpesvirus type 1 (EHV-1) as the delivery vector. EHV-1, a
member of the genus Varicellovirus in the subfamily Alphaherpesvirinae
[15], is endemic in many horse populations and causes mild to
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and neurological disorders [16]. EHV-1 has a double-stranded
DNA genome 150 kbp in length, with numerous nonessential
genes that allow insertion of foreign sequences. The potential of
EHV-1 as a universal immunization vector is highlighted by its
high efficiency in delivering foreign genes in a wide variety of cells
and the lack of anti-vector immunity in non-equine hosts [17,18].
EHV-1 strain RacH, attenuated by continuous passaging on
primary swine kidney cells, is currently used as a modified live
vaccine (MLV) against EHV-1 infection in the US and Europe
and has an excellent safety record [19]. This vaccine strain has
been established as an infectious bacterial artificial chromosome
(BAC), which makes manipulation of the virus genome easily
accessible [20]. Based on the RacH strain, live-vectored vaccines
have been developed against various viruses, which were shown to
induce both humoral and cellular immune responses and provide
protection in vaccinated animals, including mice, dogs and cattle
[19,21,22,23,24].
Lately, interferon a/b receptor-deficient (IFNAR
2/2) mice have
been established as a novel small animal model of BTV infection
[25]. IFNAR
2/2 mice are impaired in their innate immune
responses [26] and were shown to be highly susceptible to BTV
infection, but they can be completely protected by vaccination,
making them an ideal tool for BTV vaccine research [25].
Here, we describe the construction and evaluation of two EHV-
1 RacH-based recombinant vaccines against BTV-8 expressing
the immunodominant outer capsid protein VP2 alone or in
combination with VP5. We show that both recombinant EHV-1
mutants stably express the transgenes and induce a BTV-8-specific
neutralizing antibody response. In the IFNAR
2/2 mouse model,
VP2 alone was unable to protect mice against BTV-8 challenge;
however, substantial protection was observed when VP2 and VP5
were used in combination. VP7 was not included in the
recombinant vaccines and was used as a DIVA marker.
Results
Construction of recombinant viruses
EHV-1 ORF1 and ORF2 have been shown to be dispensable
for virus growth, are absent in the vaccine strain RacH
[19,22,27,28] and were chosen as the target region for transgene
insertion. To avoid potential recombination of the CMV promoter
upstream of egfp in mini-F sequences with the CMV promoter
controlling transgene expression, parental pRacH1 was modified
such that the CMV promoter upstream of egfp was replaced with
an EF-1a promoter using two-step Red mutagenesis. Based on the
modified pH1_EF1 BAC, a BTV-8 VP2 expression cassette was
inserted in the ORF1/2 deletion region, resulting in
pH1_EF1_VP2. In a next step, the BTV-8 VP5 gene with an
upstream internal ribosome entry site (IRES) was inserted
downstream of VP2, resulting in pH1_EF1_VP2_5 (Fig. 1). The
intervening IRES sequence serves as a ribosome-binding site for
the internal initiation of translation in a cap-independent fashion
[29]. VP2 and VP5 were separated by the IRES sequence such
that the two genes could be co-expressed as a single transcriptional
unit under the control of the common upstream HCMV IE
promoter. The correct genotype of all mutant BACs was
confirmed by RFLP analysis using BamHI or HindIII digestion.
Upon transfection of BAC DNA into RK13 cells, the recombinant
viruses, rRacH1_EF1, rH_EF1_VP2 and rH_EF1_VP2_5 were
reconstituted. The expression of gp2 was repaired in the viruses by
co-transfection of RK13 cells with viral DNA and plasmid DNA
containing full-length gene 71, and the final mutants, rRacH1,
rH_VP2 and rH_VP2_5 were generated. The VP2 and VP5 genes
were sequenced in the recombinant viruses, which ensured that no
mutations occurred during the recombination processes (data not
shown).
Transgene expression and in vitro growth properties of
the recombinant viruses
To determine whether the recombinant viruses expressed VP2
and VP5, IFA and western blot analyses were performed. Using
VP2 mAb 13C10, a specific signal could be detected in cells
infected with either rH_VP2 or rH_VP2_5, but not in cells
infected with the parental rRacH1 virus. As a control, EHV-1 gp2
expression could be detected in cells infected by either of these
viruses (Fig. 2A). Because a specific mAb against VP5 was not
available, the expression of VP5 could not be tested using IFA. In
western blot analyses using sheep anti-BTV-8 hyperimmune sera,
a specific band with a size of around 60 kDa could be detected in
Figure 1. Schematic illustration of the construction strategies
of the recombinant viruses. (A) The organization of the left terminus
of the EHV-1 RacH genome showing that ORF1 and ORF2 are absent.
UL: unique long; US: unique short; IR: internal repeat; TR: terminal
repeat. (B) A fragment released from transfer plasmid pEP-VP2 by I-CeuI
digestion was used to recombine with RacH genome, resulting in an
intermediate kanamycin (aphAI cassette)-resistant BAC clone. After I-
SceI digestion, kanamycin was removed in the following step of en
passant mutagenesis (in box) to generate VP2-expressing virus. (C) With
another round of en passant mutagenesis, VP5 gene with an IRES
sequence upstream were inserted in between VP2 and BGH polyA, and
a final construct expressing both VP2 and VP5 (D) was generated.
doi:10.1371/journal.pone.0034425.g001
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Vero cells but not in those from rH_VP2- or rRacH1-infected cells
(Fig. 2B). We concluded from the specificity of detection and the
size of the reactive band that VP5 was expressed from
rH_VP2_VP5 but not from the other two viruses. Consistent
with the IFA results, VP2, with a predicted mass of 106kDa, could
be detected in RK13 cells infected with rH_VP2 or rH_VP2_VP5,
but not in those infected with rRacH1 (Fig. 2B). Both VP2 and
VP5 recombinant proteins were shown to co-migrate with wild-
type virus proteins from Vero cells infected with BTV-8 (Fig. 2B).
Expression of VP2 and VP5 remained stable during continuous
virus passage in RK13 cells as tested by both IFA and western
blotting after 10 passages.
Knowing that the transgenes were stably expressed, the in vitro
growth properties of the recombinant viruses were compared with
those of parental virus rRacH1. The ability of the viruses to spread
from cell to cell was determined by comparison of relative plaque
areas. With the insertion of the VP2 expression cassette or VP2
and VP5 in combination, the recombinant viruses displayed
reduced plaque areas that were about 20% smaller than those
formed by rRacH1 when measured on day 3 p.i. (P,0.05)
(Fig. 2C). To further examine the replication properties of the
recombinant viruses, single-step growth kinetics were determined.
We could demonstrate that both extracellular and intracellular
titers of rH_VP2 and rH_VP2_5 were comparable with those of
parental rRacH1 during a 36 h period (Fig. 2D). The results
revealed that rH_VP2 and rH_VP2_5 were only slightly impaired
in terms of cell-to-cell spread, but that infectious virus production
was not affected by the insertion and expression of the BTV-8
antigens.
Vaccination with rH_VP2 and rH_VP2_5 induces a
neutralizing antibody response against BTV-8
To determine if the recombinant viruses can induce neutralizing
antibody responses against BTV-8, pilot vaccination of Balb/c
mice was conducted. The mice were immunized twice by the IN
or SC route with rH_VP2, rH_VP2_5 or rRacH1, and the
neutralizing antibody titers were measured using a standard serum
neutralization test (SNT). Neutralizing antibodies were detected in
mice inoculated with either rH_VP2 or rH_VP2_5, but not in
mice that had been inoculated with rRacH1 (Fig. 3). While
neutralizing antibodies were detected as early as day 14 in mice
immunized by the SC route with rH_VP2 or in mice vaccinated
with rH_VP2_5 by either route, neutralizing activity was
detectable only from day 35 (2 weeks after booster immunization)
in mice receiving rH_VP2 IN. For rH_VP2_5, the antibody titer
after immunization by the SC route was also higher, albeit not
significantly, than that after IN immunization, with a maximum
difference on day 35 (P=0.12, T-test). When the two recombinant
viruses were compared, the neutralizing antibody response
induced by rH_VP2_5, although slightly weaker at day 14 and
day 28 than that induced by rH_VP2 given by the SC route,
reached significantly higher levels on day 35 (P=0.04, T-test)
(Fig. 3). On the basis of these results, we concluded that both
rH_VP2 and rH_VP2_5 were able to induce a specific anti-BTV-
8 antibody response in vivo and that rH_VP2_5 was more effective
Figure 2. Expression of the transgenes and in vitro growth properties. (A) RK13 cells were infected with parental rRacH1, rH_VP2 or
rH_VP2_5 at an m.o.i of 0.0001. Two days post infection, cells were fixed and incubated with anti-VP2 mAb 13C10 or anti-EHV-1 gp2 mAb 3B12,
followed by Alexa Fluor 568-conjugated goat anti-mouse IgG. Fluorescence signal was inspected under the inverted fluorescence microscope. Bar
indicates 50 mm. (B) Cell lysates infected by rRacH1, rH_VP2, rH_VP2_5 or BTV-8 were separated by 10% SDS-PAGE and analysed by Western blot.
Expression of VP2 and VP5 was detected using primary antibody 13C10 and sheep anti-BTV-8 hyperimmune sera, respectively. EHV-1 MCP was used
as a control and detected with mAb 3G4. (C) RK13 cells were infected by the individual virus at an m.o.i of 0.0001 and overlaid. Three days post
infection, plaques were photographed and the areas were measured. For each virus, at least 50 plaques were measured. The relative plaque area was
compared to that of rRacH, which was set as 100%. * P,0.001. (D) The single-step growth kinetics of these viruses was analysed. RK13 cells were
infected by the viruses at an m.o.i of 5. Extracellular and intracellular virus titres were determined at the indicated time points.
doi:10.1371/journal.pone.0034425.g002
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response.
rH_VP2_5, but not rH_VP2, protects mice against BTV-8
challenge
To evaluate the protective efficacy of the recombinant viruses
against BTV-8 challenge, we utilized IFNAR
2/2 mice as the
infection model. After each injection, the applied dose of all
vaccine inocula was confirmed by plaque assays on RK13 cells. In
the first immunization, mice received 1.24610
6 plaque forming
units (PFU) of rRacH1, 0.96610
6 PFU of rH_VP2 and
0.80610
6 PFU of rH_VP2_5. The booster doses were
1.25610
6 PFU, 1.05610
6 PFU, and 1.67610
6 PFU, respectively.
Even though IFNAR
2/2 mice are highly susceptible to a number
of virus infections [26], all vaccinations were well tolerated and no
adverse effects were observed in any of the mice. After challenge,
all mock-vaccinated mice as well as mice that had received
rRacH1 rapidly lost weight and died or had to be euthanized by
day 6. The course of disease was slightly delayed in mice
vaccinated with rH_VP2, but all mice in this group also died by
day 7 after challenge infection (Fig. 4A&B). In contrast, mice in the
rH_VP2_5 group only transiently displayed mild disease (stilted
gait, ruffled coat) and weight loss (about 5%) by day 5, but fully
recovered by day 9 (Fig. 4A&B). All mice vaccinated with the
commercially available inactivated vaccine and the environmental
Figure 3. Neutralising antibody response was induced by the
recombinant viruses. Three-week old female Balb/c mice were
prime/booster immunised with rRacH1, rH_VP2 or rH_VP2_5. At the
indicated days (0, 14, 21, 28, 35), mice were bled and the antibody was
examined using standard serum neutralisation test. IN: intranasal; SC:
subcutaneous.
doi:10.1371/journal.pone.0034425.g003
Figure 4. Protective efficacy of the recombinant vaccines against BTV-8 challenge in IFNAR
2/2 mice. (A) Average group weights after
challenge. (B) Survival rate of IFNAR
2/2 mice after BTV-8 challenge infection. (C) BTV-8 RNA in spleen samples taken 14 days after challenge was
quantified using real-time RT-PCR targeting segment 5. The average segment 5 RNA copies per mg of spleen are shown. (D) BTV-8 virus titers in
spleen samples were determined by end-point titration of supernatants on Vero cells and shown as average TCID50 per mg of spleen. Differences in
virus titres between the groups were statistically evaluated with a Kruskal-Wallis rank sum test.
doi:10.1371/journal.pone.0034425.g004
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experiment (Fig. 4A&B).
All spleens of mice that had succumbed to BTV-8 infection
contained large amounts of viral RNA (over 1610
7 segment 5
copies per mg of spleen tissue). There was no significant difference
in viral RNA levels between mice that succumbed to the infection
in different groups (P.0.05). On average, spleens of mice
vaccinated with rH_VP2_5 contained almost 50,000-fold less
BTV-8 RNA than the spleens of mice vaccinated with rRacH1
(Fig. 4C). Only two of eight mice vaccinated with the inactivated
vaccine were positive for BTV RNA.
In contrast, up to 10
6.8 TCID50 of BTV-8 per mg of tissue were
found in spleens of perished mice. On average, spleens of mice in
the PBS group contained 10
5.661.1 TCID50 per mg of tissue,
compared to 10
5.160.6 in the rRacH1 group, and 10
3.661.4 in the
rH_VP2 group. The difference between the rH_VP2 group and
the other two groups was statistically significant (P,0.05) (Fig. 4D).
No infectious virus could be re-isolated from the spleens of mice
that had been vaccinated with rH_VP2_5 or BTVPUR.
Serum samples from surviving mice were tested in a VP7-
specific ELISA, but blood samples of mice succumbing to infection
were not available. All environmental controls stayed completely
negative in the ELISA. Mice that had been vaccinated with
rH_VP2_5 showed a clear, albeit weak, reaction in the test upon
challenge infection. Seven of eight, however, remained on the
negative side of the cut-off, compared to only one in the BTVPUR
group (Fig. 5).
Taken together, our data suggest that the EHV-1 recombinant
virus expressing VP2 and VP5 in combination but not VP2 alone
can protect against BTV-8 challenge and that the recombinant
vectored vaccine can be used as a DIVA when combined with a
commercial VP7-specific ELISA.
Discussion
Different vaccine strategies against BTV have been previously
developed, including inactivated whole virus preparations, MLV
vaccines, virus-like particles (VLPs) and vectored vaccines, of
which only inactivated and MLV vaccines have been commer-
cialized [7]. Both inactivated and MLV vaccines are highly
efficacious in inducing long-term protection in ruminants [3,30].
For inactivated vaccines, however, the cost of production is high
and repeated immunization is needed; for MLV vaccines, the risk
of causing adverse reactions in vaccinated ruminants and the
potential reassortment with circulating wild-type viruses are of
concern. The main argument against the use of either standard
inactivated or MLV vaccines is, however, that they are not DIVA
vaccines [3].
In contrast to the traditional inactivated or MLV vaccines, a
DIVA strategy can be achieved using VLPs or live-vectored
vaccines. VLPs are self-assembling structural viral proteins without
BTV nucleic acids, which are safe as a reversion to virulence or
genomic reassortment is impossible. Multivalent BTV vaccines are
also possible when VLPs are administered as a mixture [31]. High
production costs and stability issues with the assembled particles,
however, have so far prevented commercialization of this
approach.
On the other hand, vectored vaccines based on well-established
poxvirus delivery systems have been developed. Since VP2 is an
immunodominant protein harboring the most important neutral-
izing epitopes, it is usually the first candidate to be included in the
vectored vaccines, alone or in combination with other proteins. A
recombinant canarypox virus vectored vaccine co-expressing VP2
and VP5 of BTV-17 was shown to induce a sterilizing immune
response in sheep [12]. With a replication-competent capripox
virus encoding for VP2, VP7, NS1 and NS3 of BTV-2
individually, only partial protection was observed [11]. Based on
these findings, we chose VP2, alone or in combination with its
partner in the virus capsid, VP5, as transgenes expressed by
recombinant EHV-1.
The potential of EHV-1 as a universal vector for immunization
has been previously evaluated. It was shown to be very efficient in
non-equine animals, mainly due to its capacity to deliver foreign
genes in cells of various species and the lack of pre-existing anti-
EHV-1 immunity [18]. EHV-1 has been used to deliver bovine
viral diarrhea virus (BVDV) structural proteins in cattle and was
shown to induce neutralizing antibodies that were correlated with
reduced viremia and virus shedding [24]. While immunization of
cattle with the recombinant EHV-1 induced neutralizing antibod-
ies against EHV-1 as well, no cross-reactivity with bovine
herpesvirus type 1 (BHV-1), a major pathogen of cattle, was
observed [24]. This is of critical importance if a DIVA
compatibility for BHV-1 is also needed. On the other hand, the
lack of pre-existing anti-EHV-1 immunity in non-equine rumi-
nants will avoid interference with the vector itself. This might be
an issue with other vector systems such as capripox virus [11] and
bovine herpesvirus type 4 (BHV-4) [32] that naturally occur in
ruminants.
The limitations of BTV vaccine trials in natural hosts, such as
the high cost for large animals, the need for large animal facilities
of biosafety level 3 and the paucity of knowledge about their
immune systems, has been overcome recently by the establishment
of a small animal model, IFNAR
2/2 mice [25]. Due to a
deficiency in the b subunit of the IFN-a/b receptor, the mice are
Figure 5. Detection of VP7 antibody from survived mice using
ELISA. At the end of the experiment, antibody levels to BTV-8 VP7 were
determined from blood samples of the surviving mice (rH_VP2_5,
BTVPUR AlSap
TM 8, and the environmental groups) with the ID Screen BT
Competition ELISA. The OD values of samples were evaluated by
comparingthem to thekit negative control. All samples with an ODof up
to 50% of the negative control are antibody-positive. Samples with
higher ODs areconsidereddoubtful(50% to60%) or negative (over60%).
doi:10.1371/journal.pone.0034425.g005
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immunization [26], making them a versatile tool to evaluate the
immune response and protection conferred by vaccination.
Recently, IFNAR
2/2 mice have been used to test BTV vectored
vaccines based on recombinant modified vaccinia virus (MVA)
and BHV-4 [32,33].
We found that recombinant RacH co-expressing VP2 and VP5
of BTV-8 protected IFNAR
2/2 mice against a lethal challenge
infection. The mice displayed only transient and mild signs of
discomfort, but fully recovered by day 9 after infection. No
infectious virus was found in the mice, and viral RNA loads were
dramatically reduced. With VP2 alone, the course of disease was
slightly delayed, but all mice eventually succumbed to BTV-8
challenge. A similar result was reported when VP2 alone was
expressed by a BHV-4 vector, even though the challenge dose in
that experiment was much lower than the one used here [32].
These findings suggest that VP2 alone, while able to induce a
neutralizing antibody response, can hardly provide complete
protection against BTV infection. The degree of protection,
however, is much greater when VP2 is used together with the
minor outer capsid protein VP5 [13,34]. This synergy may be
derived from their close interaction in the virus particle, suggesting
a strong conformational/folding dependence of VP2 on VP5. The
presence of neutralizing epitopes not only in VP2 but also in VP5
has been postulated [4], but we did not test for antibodies to VP5
alone here.
The discriminatory potential of ELISAs based on non-structural
proteins has already been demonstrated [35,36], and those assays
would be theoretically suited for a DIVA concept with existing
inactivated vaccines. The recent BTV-8 vaccination campaigns,
however, have shown that the practical value of a non-structural
protein antibody ELISA is very limited, particularly in animals
that have been vaccinated and revaccinated repeatedly. The
carryover of non-structural proteins from culture system used to
produce the vaccines often results in antibodies to viral non-
structural proteins in vaccinated animals. While some of the
inactivated vaccines in the market are highly purified, not all
manufacturers include this cost-intensive step in their production
process [9]. In consequence, attempts at establishing a commercial
NS1 ELISA were not successful. Vaccination with inactivated
vaccines from different companies led to an increased number of
unspecific results in the test, which, consequently, was not released
by the manufacturer.
If adequate protection can be achieved without using VP7, the
well-established VP7 antibody ELISAs that are routinely used for
BTV diagnosis can be used for DIVA. We demonstrate that the
recombinant EHV-1 carrying both VP2 and VP5 protects mice
against lethal BTV-8 challenge. While the highly sensitive real-
time RT-PCR assay detected low levels of viral RNA in mice
immunized with rH_VP2_5, no infectious virus was present.
Compared to mice vaccinated with a standard inactivated vaccine,
the rH_VP2_5 mice displayed only minimal levels of VP7
antibody even after challenge.
Together with the availability of infectious clones of EHV-1
vaccine strain RacH, which allows rapid generation of transgene-
expressing vaccines, an approach based on vectored vaccines is a
valuable alternative for protection against orbivirus infections,
especially when a DIVA regimen is required.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with German
legislation on animal protection (Tierschutzgesetz). The experi-
mental procedures were approved by the respective Ethics
Committees in the federal states of Berlin (Permit No. LAGESO
I C 112 – 0424/08) and Mecklenburg-Vorpommern (Permit
No. LALLF M-V TSD/7221.3-1.1-058/10). The animal care
facilities and programs of Freie Universita ¨t Berlin and the
Friedrich-Loeffler-Institut meet all legal requirements. The
experiments were carried out as approved by the Ethics
Committees and all efforts were made to minimize suffering.
Cells and viruses
Rabbit kidney (RK13) cells [18,19,20] and Vero cells (RIE0015,
Collection of Cell Lines in Veterinary Medicine, FLI; derived from
CCL 81, ATCC, Manassas, VA, USA) were maintained in Earle’s
minimum essential medium (EMEM) supplemented with 10%
heat-inactivated fetal bovine serum, 100 U penicillin ml
21 and
0.1 mg streptomycin ml
21. EHV-1 parental viruses HDgp2 (EHV-
1 strain RacH in which gp2-encoding gene71 was replaced with a
mini-F sequence) [20], rRacH1 (HDgp2 in which gene 71 was
restored), rH_VP2 (recombinant RacH expressing VP2 of BTV-8)
and rH_VP2_5 (recombinant RacH expressing both VP2 and
VP5 of BTV-8) were propagated and titrated in RK13 cells. The
BTV-8 strain used in this study was a 2008 German isolate
passaged two times on Vero cells [37].
Plasmids and BAC mutagenesis
The complete VP2 and VP5 genes of BTV-8 were commer-
cially synthesized after codon optimization (Genscript) and cloned
as pUC57-BTV2 and pUC57-BTV5. The VP2 gene was then
PCR-amplified using Finnzymes’ Phusion high-fidelity DNA
polymerase (New England BioLabs) with two oligonucleotides
VP2-F/VP2-R (Table 1) and cloned into the BamHI and XbaI sites
of pEP-CMV-in to generate pEP-VP2. pEP-CMV-in was
previously constructed from pcDNA3 (Invitrogen) by inserting
the kanamycin resistance gene aphAI and a 18 bp I-SceI restriction
site flanked with two 50-bp duplicated sequences into the
cytomegalovirus (CMV) promoter [38]. Two fragments (161 bp
and 226 bp in length) flanked with I-CeuI restriction sites were
amplified from either side of the ORF1/2 deletion region in the
RacH genome and cloned into pUC19 to generate pUC19-
ORF1/2. The VP2-expressing cassette was released from pEP-
VP2 by digestion with SpeI and SphI, and cloned into the SpeI/SphI
sites of pUC-ORF1/2 to generate transfer plasmid pUC19-
ORF1/2-VP2. By digesting with I-CeuI, the VP2-expressing
cassette with two flanking fragments was released from pUC19-
ORF1/2-VP2 and used for the later recombination. To construct
a VP5 transfer plasmid, an IRES sequence was amplified and
cloned into the EcoRI and XbaI sites of pUC57-BTV5, resulting in
plasmid pUC57-IRES-VP5. The kanamycin resistance gene aphAI
and an I-SceI restriction site with two flanks of 40-bp each were
inserted using the XbaI site of pUC57-IRES-VP5 to generate
transfer plasmid pUC57-IRES-kan-VP5.
The EHV-1 BAC pRacH1, derived from vaccine strain RacH,
was constructed to harbor an inversion of the mini-F sequence
relative to the parental clone pRacH described elsewhere [20] to
increase genomic stability [19]. Here, pRacH1 was further
modified by replacing the HCMV promoter upstream of egfp in
the mini-F cassette with human elongation factor promoter 1a
(EF-1a) to avoid potential recombination with the HCMV
promoter present in the transfer plasmids. BAC mutagenesis was
conducted using a two-step Red-mediated (en passant) strategy [38].
Briefly, the EF-1a promoter with the I-SceI-aphAI cassette was
amplified from pEP-EF1-in using oligonucleotides EF1-ep1/EF1-
ep2 (Table 1), which carry sequences homologous to those flanking
the HCMV promoter within mini-F sequences present in
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into E. coli GS1783 [39] cells harboring pRacH1. After the first
recombination, the EF-1a promoter and I-SceI-aphAI cassette were
inserted into pRacH1, and kanamycin-resistant intermediates
were obtained. For the second recombination, 1% arabinose was
used to induce expression of the homing endonuclease I-SceI,
resulting in the cleavage of the I-SceI restriction site upstream of
the aphAI gene and, ultimately, the excision of the kanamycin
cassette. The modified BAC was termed pH1_EF1. With the same
strategy, the VP2 expression cassette was inserted in lieu of
ORF1/2 of pH1_EF1 through recombination between BAC DNA
and the fragment released by digestion with I-CeuI from pUC19-
ORF1/2-VP2, resulting in pH1_EF1_VP2. To insert the VP5
gene into pH1_EF1_VP2, two oligonucleotides VP5-ep1/VP5-
ep2 (Table 1) were used to amplify IRES-VP5 and the I-SceI-aphAI
cassette from pUC57-IRES-kan-VP5. With another round of en
passant recombination, the amplicon was inserted into
pH1_EF1_VP2 utilizing 40-bp homology flanks present in the
primers. The resulting pH1_EF1_VP2_5 BAC contained the VP2
and VP5 genes of BTV-8 separated by the IRES sequence and
controlled by the common upstream HCMV IE promoter.
The strategy for the BAC mutagenesis is illustrated in Fig. 1.
The correct construction of BAC mutants was assessed by
restriction fragment length polymorphism (RFLP) analysis and
sequencing. Virus reconstitution was performed by transfecting
1 mg of BAC DNA into RK13 cells using polyethylenimine (PEI)
(Polysciences). gp2 expression of the reconstituted viruses was
restored by co-transfection of 1 mg BAC DNA and 10 mg plasmid
p71 in RK13 cells. The recombinant EHV-1 viruses expressing
VP2 alone or VP2 and VP5 were named rH_VP2 and rH_VP2_5,
respectively.
Indirect immunofluorescence assays (IFA) and western
blotting
For IFA, confluent RK13 cells in a 6-well plate were infected
with rH_VP2, rH_VP2_5 or parental virus rRacH1 at a
multiplicity of infection (m.o.i.) of 0.0001. One hour post infection
(p.i), viruses were removed and infected cells were overlaid with
1.5% methylcellulose (Sigma) in EMEM-2% FBS. After 48 h of
incubation at 37uC, cells were washed with 16phosphate-buffered
saline (16PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4,
1.47 mM KH2PO4) and fixed in 3.5% paraformaldehyde in PBS
for 30 min at room temperature (RT), followed by a 5 min
incubation in PBS containing 30 mM glycine and another 5 min
for permeabilization using PBS with 0.1% Triton X-100. After
washing with PBS, cells were blocked with PBS-3% bovine serum
albumin (BSA) for 30 min at RT and then incubated with
monoclonal antibody (mAb) 13C10 against BTV-8 VP2 (a gift
from Dr. Malte Dauber, Friedrich-Loeffler-Institut, Insel Riems,
Germany) or 3B12 against EHV-1 gp2 [40] for 1 h at RT. After
extensive washing (3 times for 10 min), the secondary antibody
(Alexa Fluor568-conjugated goat anti-mouse IgG, Invitrogen) was
added at a dilution of 1:2,000 in PBS-3% BSA and incubated for
1 h at RT. After washing, the fluorescence signal was inspected
under an inverted fluorescence microscope and recorded with a
digital camera (Axiovert 25 and Axiocam, Zeiss).
For western blot analyses, RK13 cells were infected with the
recombinant or parental EHV-1 viruses and Vero cells with BTV-
8 wild type virus. Twenty-four hours p.i., cells were collected and
resuspended in radioimmunoprecipitation assay (RIPA) buffer
(20 mM Tris, pH 7.5; 150 mM NaCl; 1% Nonidet P-40; 0.5%
sodium deoxycholate; 0.1%SDS) with a protease inhibitor cocktail
(Roche) and benzonase (Novagen). Proteins of cell lysates were
separated using sodium dodecyl sulfate (SDS)-12% polyacrylamide
gel electrophoresis (PAGE) and transferred to a polyvinylidene
fluoride (PVDF) membrane. After blocking the membrane with
5% non-fat dry milk in PBS, the membrane was incubated with
mAb 13C10 against BTV-8 VP2, a sheep anti-BTV-8 hyperim-
mune serum [30] or mAb 3G4 against EHV-1 major capsid
protein (MCP) in blocking buffer for 1 h. The secondary antibody
was rabbit anti-mouse IgG-HRP (1:1,000) (SouthernBiotech) or
goat anti-sheep IgG conjugated with HRP (1:1,000) (Santa Cruz
Biotechnology). Reactive bands were visualized by enhanced
chemoluminescence (Amersham ECL plus, GE healthcare).
Table 1. Oligonucleotides used in this study.
Primers Sequences (59 to 39)
VP2-F CGCGGATCC ATGGAGGAGCTGGCTATCCCC
VP2-R GCTCTAGA TTACACGTTCAGAAGCTTCGTAAGC
ORF1 Fw CAGTGAATTCGACGTAACTATAACGGTCCTAAGGTAGCGAATTTTTCCATTGGGCCCCTCCC
ORF1 Rv CGCCTGCAGCTACTAGT TGGAGATGGAGACAGAGGAGG
ORF3 Fw GATC GCATGC CCCGGGGCTAAAAAGCTGCGT
ORF3 Rv GATCAAGCTGACGTAACTATAACGGTCCTAAGGTAGCGAAGGAGCAGCAGGCCCCCATCGA
EF1-ep1 TTTTGCGCACGGTTATGTGGACAAAATACCTGGTTACCCAGGCCGTGCCGGCACGTTAACCGGGCTCGTGAGGCTCCGGTGCCCGTCA
EF1-ep2 TGGTGGCGACCGGTAGCGCTAGCGGATCTGACGGTTCACTAAACCAGCTCTGCTTATATAGACCTCTCACGACACCTGAAATGGAAGA
IRES Fw CAGT GAATTC GCCCCTCTCCCTCCCCCCCCCCT
IRES Rv ATGC TCTAGA ATTATCATCGTGTTTTTCAAAGGAA
VP5-in Fw ATGCTCTAGATCCAATATGGGCAAAATCATTAAGAGCCTGTCCCGTTGGATGACGACGATAAGTAGGGATAAC
VP5-in Rv ATGC TCTAGA GGG TAA TGC CAG TGT TAC AAC CA
VP5-ep1 CATGTCTTTGGTAACGATGAGATGCTTACGAAGCTTCTGAACGTGTAAGCCCCTCTCCCTCCCCCCCCCCT
VP5-ep2 GCGAGCTCTAGCATTTAGGTGACACTATAGAATAGGGCCCTCTAGATCAGGCATTGCGAAGAAACAATGGG
pRacH-xx-F CCCTCTACGGTTTTCTTCGAGGCCG
pRacH-xx-R CCTAGGCGATGTGTGCAGCCGAGGC
doi:10.1371/journal.pone.0034425.t001
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To compare the in vitro growth properties of the recombinant
viruses with EHV-1 parental virus, plaque areas and single-step
growth kinetics were determined. Plaque areas were measured after
infection of RK13 cells at an m.o.i. of 0.0001 and overlaid with 1.5%
methylcelluloseinEMEM–2%FBS.Threedaysp.i.,IFA using mAb
A8 against EHV-1 gM [20] was performed. For each virus, 50
plaqueswere photographed and meanplaque sizeswereanalyzed by
using ImageJ software (http://rsb.info.nih.gov/ij/). For determining
single-step growth kinetics, RK13 cells seeded in 24-well plates were
infected at an m.o.i. of 5. The viruses were allowed to attach for 1 h
at 4uC, followed by a penetration step of 1.5 h at 37uC. After
washing twice with PBS, infected cells were treated with ice-cold
citratebuffered saline(pH 3.0) for3 mintoremoveresidualvirus.At
different time points (0, 4, 8, 12, 24, 36, 48 h p.i.), supernatants and
infected cells were collected separately. Extracellular and cell-
associated virus titers were determined by plaque assays. Single-step
growth curves were computed from three independent experiments.
Immunization and challenge infection of mice
In the first animal experiment, we determined whether the
recombinant viruses induced a BTV-8-specific humoral immune
response. Three-week-old female Balb/c mice (Harlan) were
allocated randomly to five groups of 6 mice each. Each mouse was
primed and booster-immunized with 1610
5 plaque forming units
(PFU) of virus in a 3-week interval. Group I was inoculated
intranasally (IN) with rH_VP2. For Group II, the same virus was
used, but the application was subcutaneous (SC). Group III and
IV were vaccinated with rH_VP2_5 IN or SC, respectively. The
mice in the control group were immunized with parental rRacH1.
Blood was collected from mice 1 day before immunization (day-1)
and on days 14, 21, 28, and 35. Serum was prepared by
centrifugation at 5000 rpm for 2 min. The antibody titers were
examined in a standard SNT [41].
In the second animal experiment, the protective efficacy of the
vectored vaccines against BTV-8 challenge was evaluated using 36
male IFNAR
2/2 mice (on a C57BL/6 genetic background), which
were provided by Dr. Markus Keller, Friedrich-Loeffler-Institut,
Insel Riems, Germany. Two groups of eight mice were inoculated
with rH_VP2 or rH_VP2_5. Four mice received parental
rRacH1. Eight mice served as positive vaccination controls and
were injected with 50 ml of a commercially available inactivated
BTV-8 vaccine (BTVPUR AlSap
TM 8, Merial, Lyon, France;
licensed for use in domestic ruminants in the European Union). A
control group of four mice was mock-vaccinated with 100 mlo f
PBS. Another group of four mice was kept in the same room as the
other mice, but was not vaccinated (environmental control). The
immunizations were given SC twice three weeks apart. Three
weeks after the second application, all mice except the environ-
mental control group were challenged by subcutaneous injection
of 5610
3 TCID50 of BTV-8 in cell culture medium. The
intraperitoneal LD50 of this strain for IFNAR
2/2 mice is about
10
21 TCID50 (M. Eschbaumer, unpublished observations). The
challenge dose was confirmed by titration on Vero cells.
Tissue sample preparation
Mice were weighed every morning, checked for signs of disease
at least twice a day, and dead mice were removed from the cages
immediately. Mice that met pre-defined exit criteria (apathy,
ruffled fur and ocular discharge or over 20% weight loss) were
anesthetized with isoflurane and killed by cervical dislocation. The
whole spleen was removed from dead or euthanized animals,
suspended in 1 ml of serum-free MEM containing antibiotics and
antimycotics, weighed and stored at 270uC until analysis.
RNA extraction and quantitative RT-PCR
For RNA extraction and virus titration, the samples were
thawed and homogenized with steel balls in a TissueLyser
(Qiagen, Hilden, Germany). Homogenized spleen samples were
centrifuged, and the supernatants removed. One hundred
microliters of supernatant were added to 300 ml of MagNA Pure
LC lysis/binding buffer (Roche Diagnostics) and total nucleic acid
was extracted using a MagNA Pure LC according to the
manufacturer’s instructions. BTV-8 RNA was detected by semi-
quantitative RT-PCR (RT-qPCR). Of 100 ml of total nucleic acid
eluate, 5 ml were used for RT-qPCR. Amplification was
performed with the AgPath-ID
TM One-Step RT-PCR kit (Applied
Biosystems/Ambion) using a ‘‘pan-BTV’’ genome segment 5 PCR
with primers and probes exactly as described [42]. In vitro
transcribed BTV-8 segment 5 RNA standard (B. Hoffmann,
unpublished; protocol available upon request) was used for
absolute quantification. BTV-8 virus titers in spleen samples of
mice were determined by end-point titration of supernatants on
Vero cells. Differences in virus titers between groups were
statistically evaluated with a Kruskal-Wallis rank sum test.
Detection of VP7 antibody using ELISA
At the end of the experiment (two weeks after challenge
infection), blood samples were taken from all surviving mice. Blood
was collected in plain tubes. After coagulation, samples were
centrifuged and sera were harvested and stored at 270uC until
analysis. Antibody levels to BTV-8 core capsid protein VP7 were
determined with the ID Screen BT Competition ELISA (ID Vet).
The optical density values (ODs) of samples are evaluated by
comparing them to the kit negative control. All samples with an
OD of up to 50% of the negative control are positive. Samples
with higher ODs are considered doubtful (50% to 60%) or
negative (over 60%).
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